Osimertinib, a third‐generation inhibitor, was designed to and has been proven to selectively target T790M.8, 9, 10 Previous clinical trials have shown the promising efficacy of this third‐generation EGFR‐TKI in patients who experience disease progression after treatment with first‐ and second‐generation EGFR‐TKIs.9, 10, 11 A phase 3 clinical trial (AURA 3) also reported enhanced PFS associated with osimertinib in comparison to standard chemotherapy in NSCLC patients with an acquired T790M mutation.12 Here, EGFR is linked to non-small cell lung carcinoma.